Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 19/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL905394 | 0.91 | TACR1 (0.79) | TACR1CYP3A4GPBAR1 | |
| SCHEMBL905366 | 0.90 | TACR1 (0.73) | TACR1CYP3A4GPBAR1 | |
| SCHEMBL6525284 | 0.89 | TACR1 (0.81) | TACR1CYP3A4GPBAR1 | |
| SCHEMBL21235997 | 0.86 | TACR1 (0.86) | TACR1CYP3A4GPBAR1 | |
| SCHEMBL905355 | 0.86 | TACR1 (0.77) | TACR1CYP3A4GPBAR1 | |
| SCHEMBL5760200 | 0.86 | TACR1 (0.77) | TACR1CYP3A4GPBAR1 | |
| SCHEMBL5760198 | 0.86 | TACR1 (0.77) | TACR1CYP3A4GPBAR1 | |
| SCHEMBL7086321 | 0.86 | TACR1 (0.74) | TACR1CYP3A4GPBAR1 | |
| SCHEMBL29467378 | 0.86 | TACR1 (1.00) | TACR1GPBAR1 | |
| SCHEMBL905330 | 0.86 | TACR1 (1.00) | TACR1GPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053954-A1 | METHOD OF TREATMENT AND/OR PREVENTION OF BRAIN, SPINAL OR NERVE INJURY | HOFFMANN TORSTEN | 2011-03-03 | — | — | US | claimed |
| EP-1394150-B1 | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists | HOFFMANN LA ROCHE (CH) | 2011-01-19 | — | — | EP | claimed |
| US-20060247240-A1 | Method of treatment and/or prevention of brain, spinal or nerve injury | HOFFMANN TORSTEN | 2006-11-02 | — | — | US | claimed |
| EP-1385577-B1 | USE OF NK-1 RECEPTOR ANTAGONISTS AGAINST BENIGN PROSTATIC HYPERPLASIA | HOFFMANN LA ROCHE (CH) | 2006-04-19 | — | — | EP | claimed |
| EP-1621195-A2 | The use of pyridinic NK-1 receptor antagonists for the treatment of brain, spinal or nerve injury | F.HOFFMANN-LA ROCHE AG (CH) | 2006-02-01 | — | — | EP | claimed |
| EP-1406618-A2 | USE OF NK-1 RECEPTOR ANTAGONISTS WITH PYRIDINIC STRUCTURE FOR THE TREATMENT OF BRAIN, SPINAL OR NERVE INJURY | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-14 | — | — | EP | claimed |
| EP-1394150-A1 | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-03 | — | — | EP | claimed |
| US-20030083345-A1 | Method of treatment and/or prevention of brain, spinal or nerve injury | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-01 | — | — | US | claimed |
| WO-2003006016-A2 | USE OF NK-1 RECEPTOR ANTAGONISTS WITH PYRIDINIC STRUCTURE, FOR THE TREATMENT OF BRAIN, SPINAL OR NERVE INJURY | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-23 | — | — | WO | claimed |
| US-20030004157-A1 | Use of NK-1 receptor antagonists against benign prostatic hyperplasia | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-02 | — | — | US | claimed |
| EP-1035115-A1 | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2000-09-13 | — | — | EP | claimed |
| US-20110053954-A1 | METHOD OF TREATMENT AND/OR PREVENTION OF BRAIN, SPINAL OR NERVE INJURY | HOFFMANN TORSTEN | 2011-03-03 | — | — | US | disclosed |
| EP-1394150-B1 | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists | HOFFMANN LA ROCHE (CH) | 2011-01-19 | — | — | EP | disclosed |
| EP-1303490-B1 | N-OXIDES AS NK1 RECEPTOR ANTAGONIST PRODRUGS OF 4-PHENYL-PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-07-09 | — | — | EP | disclosed |
| US-20060247240-A1 | Method of treatment and/or prevention of brain, spinal or nerve injury | HOFFMANN TORSTEN | 2006-11-02 | — | — | US | disclosed |
| US-20020091265-A1 | 4-phenyl-pyridine derivatives | BOS MICHAEL (CA) | 2002-07-11 | — | — | US | disclosed |
| US-20020045642-A1 | NK-1 receptor active amine oxide prodrugs | HOFFMANN-LA ROCHE INC. | 2002-04-18 | — | — | US | disclosed |
| WO-2002006236-A1 | N-OXIDES AS NK1 RECEPTOR ANTAGONIST PRODRUGS OF 4-PHENYL-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-24 | — | — | WO | disclosed |
| US-6297375-B1 | 4-phenyl-pyridine derivatives | HOFFMANN-LA ROCHE INC. | 2001-10-02 | — | — | US | disclosed |
| EP-1035115-A1 | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2000-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053954-A1 | METHOD OF TREATMENT AND/OR PREVENTION OF BRAIN, SPINAL OR NERVE INJURY | NTSR1, NTRK2, NMUR1 | TACR1 14/4885CYP3A4 3255/4885GPBAR1 430/4885 |
| US-20030004157-A1 | Use of NK-1 receptor antagonists against benign prostatic hyperplasia | KLK3, TACR1, TACR2 | TACR1 2/4885CYP3A4 1133/4885GPBAR1 84/4885 |
| US-20030083345-A1 | Method of treatment and/or prevention of brain, spinal or nerve injury | NTRK2, NTSR1, NMUR1 | TACR1 9/4885CYP3A4 3268/4885GPBAR1 333/4885 |
| US-20020045642-A1 | NK-1 receptor active amine oxide prodrugs | TACR1, BDKRB1, NPSR1 | TACR1 1/4885CYP3A4 521/4885GPBAR1 145/4885 |
| US-20060247240-A1 | Method of treatment and/or prevention of brain, spinal or nerve injury | NTSR1, NTRK2, NMUR1 | TACR1 10/4885CYP3A4 3267/4885GPBAR1 457/4885 |
| US-20020091265-A1 | 4-phenyl-pyridine derivatives | CBR1, CBR3, HCCS | TACR1 534/4885CYP3A4 908/4885GPBAR1 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.